游离肿瘤DNA的介绍与临床应用

The Introduction and Clinical Application of Cell-Free Tumor DNA.

作者信息

Li Jun, Liu Renzhong, Huang Cuihong, Chen Shifu, Xu Mingyan

机构信息

HaploX Biotechnology, Shenzhen, Guangdong, China.

出版信息

Methods Mol Biol. 2018;1754:45-65. doi: 10.1007/978-1-4939-7717-8_4.

DOI:10.1007/978-1-4939-7717-8_4

PMID:29536437

Abstract

Cell-free tumor DNA (ctDNA) is a kind of potential tumor biomarkers originated from cancer lesion in the circulating liquids. Liquid biopsy, as a minimally invasive or noninvasive manner, is a cutting-edge technology to detect ctDNA and other circulating biomarkers in the blood or other body fluids. ctDNA is mostly used for cancer patients to select targeted drugs in clinical application. In addition, ctDNA could also be applied to monitor tumor progression and recurrence. In conclusion, ctDNA is a very promising tumor biomarker for diagnosis and monitoring, which would increasingly become a routine clinical application in recent years.

摘要

游离肿瘤DNA（ctDNA）是一种源自循环液体中癌症病灶的潜在肿瘤生物标志物。液体活检作为一种微创或无创方式，是检测血液或其他体液中ctDNA及其他循环生物标志物的前沿技术。在临床应用中，ctDNA主要用于癌症患者选择靶向药物。此外，ctDNA还可用于监测肿瘤进展和复发。总之，ctDNA是一种非常有前景的用于诊断和监测的肿瘤生物标志物，近年来将越来越多地成为常规临床应用。